Fulgent Genetics, Inc. (NASDAQ:FLGT) is reporting second quarter financial results on Tuesday 4th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, FLGT is expected to report 2Q20 loss of $ 0.02 per share from revenue of $ 10.02 million.
For the full year, analysts anticipate top line of $ 45.02 million, while looking forward to income of $ 0.12 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 40.00 million ~ $ 40.00 million
Click Here For More Historical Outlooks Of Fulgent Genetics, Inc.
Previous Quarter Performance
Fulgent Genetics, Inc. reported loss for the first quarter of $ 0.03 per share, from the revenue of $ 7.75 million. The quarterly revenues compared with the same quarter last year. The consensus estimates are income of $ 0.02 per share from $ 7.74 million in revenue. The bottom line results missed street analysts by $ 0.05 or 250 percent, at the same time, top line results outshined analysts by $ 0.01 million or 0.13 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Fulgent Genetics, Inc.
Stock Performance
According to the previous trading day, closing price of FLGT was $ 28.42, representing a 324.18 % increase from the 52 week low of $ 6.70 and a 1.66 % decrease over the 52 week high of $ 28.90.
The company has a market capital of $ 619.85 million and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”FLGT” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Fulgent Genetics, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.fulgentgenetics.com
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions.
